Longterm low-dose therapy with macrolides in cystic fibrosis
Abstract
Background – Modulation of the immune response is an attractive alternative approach to therapy in CF. In this regard macrolides with their additional anti-inflammatory properties may be useful in the treatment of CF lung disease. Objective – to assess action and potential mechanisms of long-term low-dose therapy with 15- and 14-member lactone ring macrolides in children with CF. Methods – Twenty-five CF patients (14 m, 11f; age range 6.5–16 yrs) were treated with azithromycin (SUMAMED®) in the dose 250 mg 2 times a week or clarithromycin in dose 250 mg every other day and basic therapy (ensymes; mucolytics, including rhDNAse; vitamins). The patients were routinely evaluated every three months. This evaluation included anthropometric measurements (Wt/Ht, %), physical examination, pulmonary function test (FEV1, FVC), microbiology of sputum (respiratory cultures), inflammatory markers in the sputum samples (neutrophil elastase activity, TNF-α, IL-4, IL-8, IFNγ concentrations) and in peripheral blood (sensitivity of lymphocytes to antiproliferative effect of glucocorticoids). Results – During the six-month period before the start of macrolides most patients had experienced a decline in FVC and FEV1 (-3.3±2% and -2±1.5% predicted, respectively). Following the treatment the lung disease progression became slower (FVC: 7.0±2.1% and FEV1: 7.1±2.1%, both p=0.02). The effect was more pronounced in the patients with FVC<70 %. Before macrolides treatment this subjects showed a loss of the mean semiannual changes in FVC (-6.0±3.0%) and FEV1 (-3.3±2.4%). After six month treatment with macrolides we noticed a significant improvement in lung function (FVC: 8.6±3.6 %, FEV1: 9.4±3.0%, both p=0.03). The patients with poor lung function showed an essential elevation of neutrophil elastase activity (from 60.0±15.1 to 130.1 ±30.4 U/mg protein; p=0.05) and decrease of TNF-β (from 68.0±34.1 to 9.3±2.3 lU/mg protein; p=0.02) in their sputum. Authors postulate that elastase activity elevation is associated with destruction of neutrophils following the antiinflammatory treatment. Discussion – Our preliminary findings suggest some potential mechanisms, by which long-term low-dose 15- and 14-member lactone ring macrolides therapy may be beneficial in CF.
About the Authors
T. V. LubskayaRussian Federation
N. I. Kapranov
Russian Federation
N. J. Kashirskaya
Russian Federation
L. A. Shabalova
Russian Federation
A. L. Pukhatsky
Russian Federation
G. V. Shmarina
Russian Federation
S. N. Kokarovtseva
Russian Federation
References
1. Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике. Смоленск: Русич; 1998.
2. Певницкий Л Л ., Пухальский А.Л., Капранов Н.И. и др. Иммунологический мониторинг больных муковисцидозом. Значение различных лабораторных показателей. Вестн. РАМН 2000; 5: 40—46.
3. Самсыгина Г.А. Макролиды. В мире лекарств 1999; 3—4: 67—72.
4. Чучалин А.Г. Актуальные проблемы пульмонологии. В кн.: Сборник трудов Всероссийского науч. о-ва пульмонологов. М.; 2000. 362—373.
5. Labro М. Anti-inflammatory activity of macrolides: a new therapeutic potential? J. Antimicrob. Chemother. 1998; 41 (suppl.B): 37—46.
6. Anstead М., Kuhn R., Hartford L. et al. Effect of chronic azithromycin on lung function in cystic fibrosis. In: North American on cystic fibrosis conference. Berlin; 1999. Abstr. 421.
7. Pirzada O., Taylor C. Long term macrolide antibiotics improve pulmonary function in cystic fibrosis. Ibid. Abstr. 348.
8. Warner J.О. Immunology of cystic fibrosis. Br. Med. Bull. 1992; 48 (4): 893—911.
9. Hoiby N. Pseudomonas in cystic fibrosis: past, present, future: The Joseph Levy Memorial Lecture. Montreal; 1998.
Review
For citations:
Lubskaya T.V., Kapranov N.I., Kashirskaya N.J., Shabalova L.A., Pukhatsky A.L., Shmarina G.V., Kokarovtseva S.N. Longterm low-dose therapy with macrolides in cystic fibrosis. PULMONOLOGIYA. 2001;(3):41-45. (In Russ.)